Home > Boards > US Listed > Biotechs > NanoViricides Inc. (NNVC)

Highlights of Today's CEO Interview with Ludlow Capital.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (6) | Next 10 | Previous | Next
DaysOnTheBeach Member Profile
Followed By 7
Posts 2,291
Boards Moderated 0
Alias Born 07/31/06
160x600 placeholder
NanoViricides Drug Candidates to be Tested in Animal Models of Dermal, Ocular and Genital Herpes Virus Infection at the Unive... PR Newswire (US) - 3/19/2018 11:12:00 AM
NanoViricides Files Quarterly Report for Period Ending December 31, 2017 PR Newswire (US) - 2/21/2018 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/20/2018 1:55:19 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 2/14/2018 5:57:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/15/2017 10:29:10 AM
Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates PR Newswire (US) - 12/6/2017 7:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/22/2017 4:23:23 PM
NanoViricides Files Quarterly Report for Period Ending September 30, 2017 PR Newswire (US) - 11/20/2017 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/14/2017 5:25:18 PM
Revised Proxy Soliciting Materials (definitive) (defr14a) Edgar (US Regulatory) - 11/8/2017 5:18:02 PM
NanoViricides Provides Further Details on Its Herpes-Induced Acute Retinal Necrosis Animal Study to be Presented On November ... PR Newswire (US) - 11/6/2017 7:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/27/2017 6:08:02 AM
Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Cente... PR Newswire (US) - 10/26/2017 7:00:00 AM
NanoViricides to Present Results On Successful Treatment Of Herpes-Induced Acute Retinal Necrosis at the Annual Meeting of th... PR Newswire (US) - 10/17/2017 7:00:00 AM
NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials PR Newswire (US) - 9/29/2017 7:30:00 AM
Annual Report (10-k) Edgar (US Regulatory) - 9/28/2017 4:51:22 PM
NanoViricides, Inc. Announces its CEO Dr. Seymour to Present at the 19th Annual Rodman & Renshaw Global Investment Conference... PR Newswire (US) - 9/11/2017 9:04:00 AM
NanoViricides Reports Its Drug Candidates Significantly Reduced the Extent of Shingles Virus Infection of Human Skin PR Newswire (US) - 7/10/2017 7:00:00 AM
NanoViricides' Poster "Novel NanoviricidesĀ® Highly Effective Against Varicella Zoster Virus in Cell Culture" to be Presented... PR Newswire (US) - 6/26/2017 9:00:00 AM
NanoViricides Abstract Accepted for Poster Presentation at the 2017 Annual Meeting of American Society of Virology PR Newswire (US) - 6/20/2017 7:00:00 AM
NanoViricides CEO to Present Information on Its Topical Shingles Treatment At the 2017 Marcum Investor Conference in New York... PR Newswire (US) - 6/13/2017 7:00:00 AM
NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell ... PR Newswire (US) - 6/6/2017 5:30:00 PM
NanoViricides Files Quarterly Report for Period Ending 2017-03-31 PR Newswire (US) - 5/16/2017 7:50:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/15/2017 5:03:04 PM
NanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 in Las Vegas; Compan... PR Newswire (US) - 4/26/2017 5:00:00 PM
DaysOnTheBeach   Monday, 04/27/09 09:31:49 PM
Re: None
Post # of 138207 
Highlights of Today's CEO Interview with Ludlow Capital.

Ludlow Capital Group today posted an 18 1/2 minute interview with NanoViricides CEO Eugene Seymour that was conducted by telephone two days ago on the 25th.

The interview is very interesting relative to the current Swine Flu outbreak, and contains some new information about the company's progress toward licensing of it's Flu and HIV drugs.

I have gone through the 18 minute 30 second interview and summarized what I believe to be several important passages, which I present below.

I also was able to "clean up" some of the telephone hum and balance out some of the audio levels, making the interview much easier to understand and more pleasant to listen to. I've uploaded this cleaned up file to some server space:

Dr. Eugene Seymour, CEO NanoViricides, interviewed by Ludlow Capital Group on 4/15/2009

00:00 -- Intros and background of flu viruses. How viruses enter cells and replicate.

07:00 -- Traditional ways to deal with viral illness 1) with vaccines, and 2) with Tamiflu and similar drugs which are typically administered after symptoms develop and attempt to interfere with viral replication.

09:40 NanoViricides presented Flu-Cide data to a major pharma two months ago, demonstrating "excellent results . . . so much better than Tamiflu". The major pharma expressed an interest in moving forward with Flu-Cide.

11:20 -- How NanoViricides' drugs attack viruses, and why they are broad spectrum.

13:15 -- NanoViricides has been spending it's time on HIV and is "in discussions with multiple pharma companies now about our HIV drug . . . we feel that we can achieve what is called a 'functional cure' [for HIV]". CEO Seymour explained his use of the term "functional cure" and described how it is achieved.

15:10 -- Dr. Seymour gave his opinion on the current Swine Flu outbreak, saying "this could be it [could become a pandemic] . . . showing all the signs of 1917 [the beginnings of the Spanish Flu pandemic] . . . it's a perfect storm". CEO Seymour explained what disease characteristics are most conducive to the creation and sustainability of a pandemic.

16:40 -- "We're rushing as fast as we can to build the manufacturing capability to produce a large amount of our drug . . . when you take it it eradicates the virus in the body".

Thank you to Ludlow Capital Group for conducting this interview!

Best to all.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (6) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist